Neuropsychiatric Events With Subcutaneous Foslevodopa/Foscarbidopa: 19.2% Incidence, Few Discontinuations
This prospective Spanish registry analysis gives pharmacists real-world incidence, timing, and risk-factor data on neuropsychiatric adverse events with foslevodopa/foscarbidopa subcutaneous infusion in patients more neuropsychiatrically vulnerable than those in pivotal trials.
📅 Journal publication: Jul 2026·Last updated: Nov 20, 2026
Subcutaneous infusion in Parkinson's shows mild neuropsychiatric risks.
Understanding neuropsychiatric adverse events in Parkinson's patients receiving continuous infusion helps optimize treatment and patient safety. In a cohort of 214 patients, 19.2% experienced neuropsychiatric adverse events, mainly mild to moderate, with only 2.3% requiring device removal. The study highlights low risk of severe events with foslevodopa/foscarbidopa infusion, underlining the importance of monitoring patients with impulse control disorders (ICDs). Continuous subcutaneous infusion is generally safe for Parkinson's patients, but requires monitoring for impulse control disorder risks.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Campo-Caballero D, Rodriguez-Antiguedad J, Puig-Davi A, Ruiz-Martinez J, Vinagre-Aragón A, Mondragón E, Vilella LP, López-Ariztegui N, Caballol N, González-Ortega G, Cabo I, Ramos RG, Legarda I, Blázquez-Estrada M, Sánchez-Alonso P, Mir P, Fábrega JCR, Martinez SM, Sauco MÁ, Santos-García D, DATs‐PD GETM Spanish Registry Group
Citation:Campo-Caballero D, Rodriguez-Antiguedad J, Puig-Davi A, et al. Neuropsychiatric Adverse Events Associated With Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Clinical Practice: A Multicenter Study. European journal of neurology. 2026;33(7):e70693. doi:10.1111/ene.70693